Narrow-moat CSL reiterated fiscal 2024 guidance for constant-currency group net profit after tax before amortization of USD 2.9 billion to USD 3.0 billion, implying 13%-17% growth on fiscal 2023. The ...

Narrow-moat CSL reiterated fiscal 2025 guidance for constant-currency group net profit after tax before amortization, or NPATA, of USD 3.2 billion to USD 3.3 billion, implying 10%-13% growth on fiscal ...

Shares of the Australia-based CSL Ltd. (AU:CSL) fell by over 4% as of writing despite the company achieving higher profit in FY24. The company reported an NPAT (net profit after tax) attributable to ...

After shocking investors in 2025, CSL shares may be setting up for a comeback. Here’s why 2026 could look better. The post Could CSL shares outperform the ASX 200 in 2026? appeared first on The Motley ...

Should you be buying the dip? Let's find out. The post Why did CSL shares crash 39% in 2025? appeared first on The Motley Fool Australia.

ADRs of CSL Limited (OTCQX:CSLLY) dropped ~16% on Tuesday as Wall Street reacted to Australian biotech’s plans to lay off 15% of its workforce, announced in conjunction with its fiscal 2025 financials ...

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring ...

CSL Limited has left its current fiscal year financial guidance unchanged, which I deem to be too conservative. There are various indicators suggesting that the company's actual topline expansion and ...

Jefferies analyst David Stanton maintained a Buy rating on CSL (CMXHF – Research Report) on January 17 and set a price target of A$341.00. The company’s shares closed last Friday at $163.15. Discover ...

Australian biotech giant CSL Ltd CSL.AX' reported on Tuesday a net profit rise of 13% in the first half, bolstered by strong demand and increased plasma collection at its Behring unit. The company, ...

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring ...